Clinical Report: A novel nomogram utilizing tumor burden for assessing SEGC
Overview
This study developed and validated a prognostic nomogram for synchronous esophageal and gastric cancers (SEGC) that incorporates age, treatment modality, and a Combined EG_Stage framework. The model demonstrated modest discrimination and was validated using an external cohort.
Background
Synchronous dual-primary esophageal and gastric cancers (SEGC) are rare but challenging malignancies that complicate prognostic assessment due to differing tumor burdens. Traditional staging systems often fail to adequately represent the complexities of these coexisting tumors.
Data Highlights
Metric
Value
C-index (external cohort)
0.681
1-year AUC
0.616
3-year AUC
0.674
5-year AUC
0.640
Median OS (high risk vs low risk)
41 vs 22 months
Key Findings
The nomogram includes age, treatment modality, and Combined EG_Stage as prognostic factors.
Internal validation showed satisfactory calibration at 1-, 3-, and 5-year time points.
The external validation cohort yielded a C-index of 0.681.
Time-dependent AUCs for overall survival were 0.616, 0.674, and 0.640 at 1, 3, and 5 years, respectively.
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
